share_log

Inhibikase Therapeutics Gets FDA Go-Ahead for Leukemia Trial of IkT-001Pro; Shares Surge Pre-Bell

Inhibikase Therapeutics Gets FDA Go-Ahead for Leukemia Trial of IkT-001Pro; Shares Surge Pre-Bell

Inhibikase治療公司獲得FDA批准進行IKT-001Pro的白血病試驗;股價在鐘聲前飆升
MT Newswires ·  2022/08/26 09:32

Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論